Description
Sermorelin Acetate is a well-known peptide analogue. Its peptide sequence comprises 29 amino acids. This is why it is also referred to as GRF 1-29. It triggers pituitary gland to produce and release growth hormone (GH). This synthetic peptide is also used as a diagnostic tool for Growth Hormone secretion. It was believed to be the smallest segment of GHRH. Unlike human Growth Hormone (hGH), which is a direct form of GH, Sermorelin Acetate stimulates the body’s natural production growth hormone, making it a growth hormone secretagogue.
Additionally, both Sermorelin Acetate and Modified GRF 1-29 are made up of 29 amino acids, while hGH has 191 amino acids.
Moreover, this Growth hormone-releasing hormone (GHRH) has shown promising results in a range of uses – right from anti-aging to treating growth hormone deficiency in children. Its anti-ageing properties have shown good outcomes for men, especially when combined with testosterone. The peptide addresses deeper issues in the GH neuroendocrine axis, has stronger physiological effects, and is not subject to restrictions for use in treating adult hormone deficiencies.
Sermorelin is a peptide analogue of GHRH (growth hormone–releasing hormone) consisting of 29 amino acids that represent a fragment of the natural human GHRH. It is the shortest synthetic peptide capable of performing all the functions of GHRH, making it a growth hormone secretagogue.
In research, Sermorelin is utilized to trigger the release of GH from the adenohypophysis or anterior pituitary, which produces trophic hormones. Sermorelin is also applied in stimulation tests during research to evaluate pituitary functions concerning growth hormone secretion.
GHRH is a polypeptide made of 44 amino acids that stimulate GH release from the anterior pituitary. Also known as somatocrinin or somatoliberin. GHRH is synthesized in certain neurons in the brain called periventricular arcuate neurons. From there, it is transported to the neurosecretory terminals of the neurons, where it is released. The arcuate neurons are a portion of the hypothalamo-hypophyseal portal system. GHRH is released from the neurosecretory terminals and occurs in a pulsatile manner, leading to a corresponding pulsatile release of growth hormone (GH). GHRH interact with a secretin-type, G-protein coupled serpentine receptor known as the GHRH-receptor (GHRHR).
When GHRH binds to its receptors, it activates two pathways: the cAMP (cyclic Adenosine Monophosphate)-dependent pathway and the phospholipase C (PLC) pathway. The cAMP-dependent pathway increases the transcription of the GH and GHRHR genes, creating a positive feedback loop that boosts GH production. The GH formed is subsequently packaged into secretory vesicles. The downstream effects of the PLC pathway cause these vesicles to fuse with the cell membrane, allowing GH to be released into the bloodstream through Na+-voltage-dependent and Ca2+-dependent processes.
GH supports proper and well-regulated after-birth growth and helps maintain energy balance. Research has also demonstrated that GHRH also promotes slow-wave NREM (non-rapid eye movement) sleep, while a lack of GHRH reduces both the duration and depth of slow-wave NREM sleep. This leads to sleep disorders like insomnia or dyssomnia, which prevent sleep from being restorative. Studies further indicate that GHRH suppresses the actions of somatostatin, a polypeptide hormone that blocks GH secretion from the adenohypophysis (anterior pituitary). GHRH and somatostatin are made in the same neuron but are released alternately, resulting in the secretion of GH.
